Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer

NCT02529579 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

187

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Pancreatic Ductal

Interventions

OTHER: iAPA-DC/CTL adoptive cellular immunotherapy
DRUG: Gemcitabine

Sponsor

Changhai Hospital

Collaborators

[object Object]